×
To start your customized experience click the start button
Customize
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Pancreatic

Feature Video
Pancreatic cancer may be one of the more difficult cancers to be diagnosed with. This program discusses the risk factors, symptoms, and different treatments available to patients with pancreatic cancer as well as firsthand experiences and advice from a Pancreatic patient and her husband.
Katie Kosko
Patients and providers shared inspiring stories of hope, as well as some tips for better living at the Seventh Annual Ruesch Center Symposium: Fighting a Smarter War on Cancer. 
Brielle Urciuoli
Recent-onset diabetes can lead to poorer outcomes in pancreatic cancer, according to a recent study.
Beth Fand Incollingo
After being diagnosed with pancreatic cancer, a PR executive created on online database where patients can connect with others who share their diagnosis and also get reliable information. 
Greg Kennelty
Eileen O'Reilly discusses the current barriers in treating pancreatic cancer, as well as what she sees for the future of the disease. 
Andrew J. Roth
What can online searches tell about a potential cancer diagnosis? Scientists at Microsoft are interested in finding out. 
Virginia Powers
The addition of Onivyde to some chemotherapy regimens for pancreatic cancer improved survival and did not affect patients' quality of life. 
Ellie Leick
Genetic mutations that were traditionally known for breast and ovarian cancer are now being examined for their role in pancreatic cancer. 
John Otrompke
Tumor Treating Fields were determined safe to use as a fronline therapy for unresectable pancreatic cancer. 
Beth Fand Incollingo
In a phase 3 trial, five-year overall survival was nearly doubled when capecitabine was added to gemcitabine for patients with pancreatic cancer. 
Jason M. Broderick
Algenpantucel-L failed to improve OS for patients with pancreatic cancer in a phase 3 trial. 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable